PolyMedix

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced today that Nicholas Landekic, President and CEO will present an overview and update on the company at the Rodman & Renshaw 8th Annual Healthcare Conference being held in New York, November 6-8, 2006.

PolyMedix Receives Patent Related to its Antibiotic and Antimicrobial Programs

October 19, 2006

PolyMedix, Inc. (OTC BB: PYMX) announced today that the U.S. Patent and Trademark Office has issued the company U.S. Patent No. 10,471,028 for a patent relating to its antimicrobial compounds. The patent titled, Facially Amphiphilic Polymers as Anti-infective Agents allows compositions of matter and uses for a number of series ofantimicrobial compounds for antibiotic and other anti-infective applications. “This patent represents a significant and strategic accomplishment for PolyMedix. It is the first allowance from our series of applications relating to our antimicrobial program – a program in which we are developing novel antibiotics and antimicrobial biomaterials consisting of small molecule and polymer mimics of the host defense proteins. We remain excited about the advances we are making in this promising program,” commented Nicholas Landekic, President and Chief Executive Officer.

PolyMedix to Present Data on Novel Antibiotics Under Development at the 46th Annual ICAAC

September 27, 2006

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced today that it will be presenting pre-clinical data on its antibiotic compounds in a poster presentation at the 46th annual meeting of the American Society for Microbiology's (ASM's) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. More than 12,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the problem of infectious diseases.

PolyMedix Stock Begins Trading on the Over-The-Counter Bulletin Board

July 25, 2006

PolyMedix, Inc. announced today that its Common Stock has begun trading on the Over-The-Counter Bulletin Board under the symbol PYMX. The company completed all necessary filings and received clearance from both the Securities Exchange Commission (SEC) and National Association of Securities Dealers (NASD).

PolyMedix Receives $3 Million Advanced Technology SBIR Grant

March 21, 2006

Funds will be used to support development of new antibiotic drugs.

PolyMedix Appoints New Directors

March 13, 2006

William Kelley, M.D. and Shaun O’Malley elected to Board of Directors.

PolyMedix Appoints Edward Smith Vice President Finance & CFO

March 6, 2006

Philadelphia 03 / 06 / 2006 POLYMEDIX APPOINTS EDWARD SMITH VICE PRESIDENT FINANCE & CFO “We are pleased to have Ed join our senior management team. He brings to PolyMedix his solid financial experience, particularly in the biopharmaceutical arena, and will be an invaluable contributor to our corporate governance, corporate finance, financial reporting and treasury management activities,” commented Nicholas Landekic, President and C.E.O. of PolyMedix.

PolyMedix Raises $21 Million in Equity Financing

February 21, 2006

Company Will Register its Common Stock with the SEC PolyMedix Inc. announced today that it has closed the final round of a financing in which it raised a total of $21.2 million in gross proceeds. The financing consisted of the sale of shares of Series 1 Preferred Stock, which are convertible into the Company’s common stock. In connection with the transaction, PolyMedix completed a merger with another entity in which PolyMedix was the surviving company (in a transaction structure commonly called a “reverse merger”). Fordham Financial of New York served as the placement agent for the offering.

PolyMedix today announced the resignation of Dr. Timothy Henkel, Vice President of Drug Development.

February 10, 2006

"We would like to thank Tim for his expertise and contributions to PolyMedix and remain supportive of Tim’s personal and career interests. We wish him every success in his new endeavors,” commented Nicholas Landekic, President & C.E.O. of PolyMedix.

Press releases contain forward-looking statements that involve risks and that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," “hopes,” "estimates," "looks," "expects," "plans," "intends" and similar expressions. Among other things, there can be no assurance that PolyMedix’s compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forwardlooking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Request Information and Directions to PolyMedix

Contact

Safe Harbor Statement | Privacy Policy | Terms of Use